DESTINY-Breast03: Trastuzumab Deruxtecan vs Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

⚠️ Updated analysis. The primary endpoint (progression-free survival by BICR) was previously reported: HR 0·33 (95% CI 0·26–0·43; nominal p<0·0001); median 28·8 months vs 6·8 months. This analysis reports updated overall survival at median follow-up of 28·4 months.

Primary endpoint (PFS by BICR): 28·8 vs 6·8 months — HR 0·33 (95% CI 0·26–0·43; nominal p<0·0001) Key secondary (Overall survival): Not reached vs not reached — HR 0·64 (95% CI 0·47–0·87; p=0·0037) Safety signal: Adjudicated drug-related interstitial lung disease/pneumonitis in 15% with trastuzumab deruxtecan (no grade 4 or 5 events)

📱 Clinic quick reference: Mobile version — save for point-of-care use

Clinical Bottom Line

DESTINY-Breast03 demonstrated that trastuzumab deruxtecan is superior to trastuzumab emtansine in patients with HER2-positive metastatic breast cancer who had previously received trastuzumab and a taxane. With extended follow-up at this prespecified second interim analysis, the overall survival advantage crossed the prespecified statistical boundary for significance — confirming that the profound progression-free survival benefit translates into a survival gain. The magnitude of improvement in response rate and duration of disease control further reinforces trastuzumab deruxtecan as the preferred second-line agent.

This trial is the definitive head-to-head comparison that displaced trastuzumab emtansine from its longstanding position as the standard second-line HER2-directed therapy. Current NCCN guidelines now list trastuzumab deruxtecan as the preferred second-line option for HER2-positive metastatic breast cancer, a change driven directly by these data. For practicing oncologists, DESTINY-Breast03 resolved the sequencing question at this treatment juncture: trastuzumab deruxtecan before trastuzumab emtansine is the new standard.

Interstitial lung disease remains the signature toxicity. While there were no fatal ILD events in this trial — a meaningful improvement over earlier T-DXd experience — the overall incidence was notable, and vigilant pulmonary monitoring is essential. The higher rates of nausea, vomiting, and myelosuppression with trastuzumab deruxtecan compared to trastuzumab emtansine also warrant proactive supportive care planning.

Trial Overview

Study Design

• Trial name and registration: DESTINY-Breast03, NCT03529110
• Design: Phase 3, randomised, open-label, multicentre, prespecified second interim analysis of overall survival (the primary endpoint of PFS by BICR was previously met at the first interim analysis)
• Randomization: 1:1 ratio, stratified by hormone receptor status (positive or negative), previous treatment with pertuzumab, and history of visceral disease
• Setting: HER2-positive unresectable or metastatic breast cancer, previously treated with trastuzumab and a taxane (second-line or later)
• Enrollment period and sites: Between July 20, 2018, and June 23, 2020; multicentre, international

This publication reports the prespecified second interim analysis of the key secondary endpoint of overall survival in the DESTINY-Breast03 trial. The primary endpoint (progression-free survival by BICR) was met at the first interim analysis (data cutoff May 21, 2021). At this second OS interim analysis (data cutoff July 25, 2022), p-values for PFS and other efficacy endpoints (except OS) are nominal.

Mechanism of Action

Trastuzumab deruxtecan (T-DXd; Enhertu) is an antibody-drug conjugate composed of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload (DXd, an exatecan derivative) via a cleavable tetrapeptide-based linker [2]. Following binding to HER2 and internalization, the linker is cleaved in the lysosome, releasing the cytotoxic payload. The membrane-permeable nature of DXd enables a bystander killing effect on adjacent tumor cells, including those with lower HER2 expression [2].

Patient Population

• Key eligibility: HER2-positive (centrally confirmed) unresectable or metastatic breast cancer previously treated with trastuzumab and a taxane in the advanced/metastatic setting (or progression during/within 6 months after neoadjuvant/adjuvant trastuzumab and taxane); age ≥18 years; ECOG PS 0–1; at least one measurable lesion per RECIST 1.1; clinically inactive or previously treated brain metastases permitted
• Biomarker selection: HER2-positive, centrally confirmed
• Sample size flow: 699 screened → 524 randomised (261 T-DXd, 263 T-DM1) → 518 treated (257 T-DXd, 261 T-DM1) → 524 analyzed (full analysis set)

Baseline Characteristics

Treatment Protocol

Experimental Arm: Trastuzumab Deruxtecan (n=261 randomised; safety population n=257)

Trastuzumab deruxtecan 5·4 mg/kg IV every 3 weeks.

• Dose and schedule: 5·4 mg/kg administered by intravenous infusion every 3 weeks
• Treatment duration: Not reported in this publication
• Median treatment duration: 18·2 months (IQR 9·0–29·4)
• Median relative dose intensity: Not reported in this publication

Control Arm: Trastuzumab Emtansine (n=263 randomised; safety population n=261)

Trastuzumab emtansine 3·6 mg/kg IV every 3 weeks.

• Dose and schedule: 3·6 mg/kg administered by intravenous infusion every 3 weeks
• Treatment duration: Not reported in this publication
• Median treatment duration: 6·9 months (IQR 2·8–12·3)

Treatment status at data cutoff (July 25, 2022): 75 (29%) patients in the trastuzumab deruxtecan group and 18 (7%) patients in the trastuzumab emtansine group remained on treatment.

Efficacy Outcomes

The primary endpoint of this trial (progression-free survival by blinded independent central review) was reported at the first interim analysis (data cutoff May 21, 2021). At this prespecified second interim analysis (data cutoff July 25, 2022; median follow-up 28·4 months for T-DXd and 26·5 months for T-DM1), updated PFS and the formally tested OS results are reported below.

Primary Endpoint: Progression-Free Survival by Blinded Independent Central Review

Definition: Progression-free survival as determined by blinded independent central review based on RECIST 1.1 Analysis population: Full analysis set (N=524) Statistical method: Stratified log-rank test; Cox proportional hazards regression model stratified by randomisation stratification factors Median follow-up: 28·4 months (IQR 22·1–32·9) for trastuzumab deruxtecan; 26·5 months (IQR 14·5–31·3) for trastuzumab emtansine

Trastuzumab deruxtecan: 28·8 months (95% CI 22·4–37·9) Trastuzumab emtansine: 6·8 months (95% CI 5·6–8·2) Comparison: HR 0·33 (95% CI 0·26–0·43; nominal p<0·0001)

Note: The p-value for PFS at this analysis is nominal, as the primary PFS endpoint was previously met at the first interim analysis.

PFS rates by timepoint:

• 12 months: 75·2% (95% CI 69·3–80·2) vs 33·9% (95% CI 27·7–40·2)
• 24 months: 53·7% (95% CI 46·8–60·1) vs 26·4% (95% CI 20·5–32·6)

Key Secondary Endpoint: Overall Survival

Definition: Time from the date of randomisation to the date of death due to any cause Analysis population: Full analysis set (N=524) Formally tested: Yes — this was the prespecified second interim analysis of OS within the hierarchical testing framework Statistical boundary: The planned p-value boundary for statistical significance at the second interim analysis was 0·008 (based on 153 planned events). This was recalculated to 0·013 based on the actual 169 OS events observed. The observed p-value of 0·0037 crossed this boundary.

Trastuzumab deruxtecan: Median not reached (95% CI 40·5 months–not estimable); 72 (28%) OS events Trastuzumab emtansine: Median not reached (95% CI 34·0 months–not estimable); 97 (37%) OS events Comparison: HR 0·64 (95% CI 0·47–0·87; p=0·0037)

OS rates by timepoint:

• 12 months: 94·1% (95% CI 90·4–96·4) vs 86·0% (95% CI 81·1–89·8)
• 24 months: 77·4% (95% CI 71·7–82·1) vs 69·9% (95% CI 63·7–75·2)

Vital status at data cutoff: 170 (65%) patients in the T-DXd group and 138 (52%) in the T-DM1 group were alive. 19 (7%) T-DXd patients and 28 (11%) T-DM1 patients were censored due to lost to follow-up.

Other Secondary Endpoints

Confirmed objective response rate by BICR Analysis population: Full analysis set Trastuzumab deruxtecan: 79% (205 patients; 95% CI 73·1–83·4) — including 55 (21%) complete responses and 150 (57%) partial responses Trastuzumab emtansine: 35% (92 patients; 95% CI 29·2–41·1) — including 25 (10%) complete responses and 67 (25%) partial responses This endpoint was not formally tested in the statistical hierarchy at this analysis.

Duration of response by BICR Analysis population: Full analysis set (responders) Trastuzumab deruxtecan: Median 36·6 months (95% CI 22·4–not estimable) Trastuzumab emtansine: Median 23·8 months (95% CI 12·6–34·7) This endpoint was not formally tested in the statistical hierarchy at this analysis.

Progression-free survival by investigator assessment Analysis population: Full analysis set Trastuzumab deruxtecan: Median 29·1 months (95% CI 23·7–not estimable) Trastuzumab emtansine: Median 7·2 months (95% CI 6·8–8·3) Comparison: HR 0·30 (95% CI 0·24–0·38; nominal p<0·0001) This endpoint was not formally tested in the statistical hierarchy at this analysis.

Exploratory Endpoints

Clinical benefit rate by BICR Analysis population: Full analysis set Trastuzumab deruxtecan: 89% (233 patients; 95% CI 84·9–92·8) Trastuzumab emtansine: 46% (122 patients; 95% CI 40·2–52·6) This is an exploratory endpoint.

Progression-free survival on the next line of therapy (PFS2) by investigator assessment Analysis population: Full analysis set Trastuzumab deruxtecan: Median 40·5 months (95% CI 40·5–not estimable) Trastuzumab emtansine: Median 25·7 months (95% CI 18·5–34·0) Comparison: HR 0·47 (95% CI 0·35–0·62) This is an exploratory endpoint.

Safety

Safety Population

Trastuzumab deruxtecan: 257 patients; Trastuzumab emtansine: 261 patients.

Safety Summary

Exposure-adjusted incidence rates: When adjusted for the longer treatment duration with T-DXd, grade ≥3 TEAE rates were lower with trastuzumab deruxtecan (0·36) than with trastuzumab emtansine (0·65). Serious TEAE rates were similarly lower: 0·16 vs 0·28.

Grade ≥3 Adverse Events of Clinical Significance

The toxicity profiles differed between arms: trastuzumab deruxtecan was associated with more myelosuppression (neutropenia, leukopenia), gastrointestinal toxicity (nausea, vomiting), and fatigue; trastuzumab emtansine was associated with more thrombocytopenia and hepatotoxicity (transaminase elevations).

Adverse Events of Special Interest

⚠️ Interstitial Lung Disease / Pneumonitis: Critical Safety Signal

• Any grade (T-DXd): 39 (15%)
• Grade 1: 11 (4%)
• Grade 2: 26 (10%)
• Grade 3: 2 (<1%)
• Grade 4: 0
• Grade 5 (fatal): 0
• Any grade (T-DM1): 8 (3%)
• Grade 1: 4 (2%)
• Grade 2: 3 (1%)
• Grade 3: 1 (<1%)
• Grade 4: 0
• Grade 5 (fatal): 0
• Adjudication: All ILD/pneumonitis events were adjudicated by an independent committee.
• Time to onset: Median 8·1 months (IQR 4·2–15·0) with T-DXd; 11·7 months (IQR 8·1–15·8) with T-DM1
• Clinical implication: While ILD was more common with trastuzumab deruxtecan, the severity profile improved compared to earlier T-DXd studies — notably, there were no grade 4 or 5 ILD events in either arm. Proactive monitoring with pulmonary imaging, patient education on respiratory symptoms, and prompt dose interruption with corticosteroid initiation for suspected ILD remain mandatory.

Deaths

• Total deaths: 169 (72 [28%] in T-DXd arm; 97 [37%] in T-DM1 arm)
• Treatment-related deaths: Not reported in this publication
• ILD-related deaths: 0 in both arms

Subgroup Analyses

These subgroup analyses were not powered for formal statistical comparisons. Results should be interpreted as hypothesis-generating.

Notable observations: The OS benefit with trastuzumab deruxtecan was directionally consistent across all subgroups, with point estimates of the hazard ratio favoring T-DXd in every subgroup. Confidence intervals for the hormone-receptor-positive, prior pertuzumab, prior lines <3, and brain metastases subgroups crossed 1·0, which likely reflects the limited number of events at this interim analysis rather than a true absence of benefit.

Key Comparator Trials

Cross-trial comparisons are limited by differences in patient populations, trial designs, and endpoints. These data are presented for context, not for direct statistical comparison.

Contextual Notes

DESTINY-Breast03 directly compared trastuzumab deruxtecan to the prior second-line standard, trastuzumab emtansine, which had been established by the EMILIA trial [4]. The magnitude of the PFS and OS improvement in DESTINY-Breast03 is among the largest seen in a randomized HER2-positive metastatic breast cancer trial, fundamentally changing the treatment algorithm.

HER2CLIMB [5] established tucatinib-trastuzumab-capecitabine for patients who had progressed on trastuzumab, pertuzumab, and T-DM1 — a later-line population than DESTINY-Breast03. Because DESTINY-Breast03 has now displaced T-DM1 from the second-line setting, the practical question becomes whether to use tucatinib-based therapy or T-DM1 in the third line after T-DXd progression. No randomized trial directly addresses this sequencing question. Notably, 42 (17%) patients in the T-DM1 arm of DESTINY-Breast03 received T-DXd as subsequent therapy, and 64 (35%) patients in the T-DXd arm received T-DM1 subsequently, confirming that the sequencing of these agents occurs in practice.

Grey Zones and Unanswered Questions

• Optimal third-line sequencing after T-DXd: DESTINY-Breast03 does not answer what the best therapy is after T-DXd progression. The exploratory PFS2 analysis (HR 0·47) suggests benefit persists even into the next line, but the choice between T-DM1, tucatinib-based therapy, or other options after T-DXd is unresolved by direct evidence.

• Impact of subsequent T-DXd use in the T-DM1 arm on OS interpretation: 42 (17%) patients randomized to T-DM1 received T-DXd as subsequent therapy. This post-protocol crossover to T-DXd could attenuate the observed OS difference, meaning the true survival benefit of upfront T-DXd may be underestimated. No crossover-adjusted OS analysis was reported.

• Brain metastases population: While patients with clinically inactive or previously treated brain metastases were eligible, the brain metastases subgroup (n=82 total) showed an OS HR of 0·54 (95% CI 0·29–1·03) that crossed 1·0. Whether T-DXd provides the same magnitude of intracranial benefit as systemic benefit remains an open question, particularly given the competing option of tucatinib-based therapy, which was specifically studied in patients with active brain metastases in HER2CLIMB.

• Hormone-receptor-positive subgroup: The OS HR in the HR-positive subgroup was 0·76 (95% CI 0·50–1·14), compared to 0·55 (0·35–0·87) in HR-negative. While the interaction is not formally tested and the confidence intervals overlap substantially, this raises the question of whether concomitant endocrine receptor signaling modifies the benefit of T-DXd — a clinically relevant issue given that approximately half of HER2-positive patients are HR co-positive.

• Long-term ILD risk with extended T-DXd exposure: The median treatment duration with T-DXd was 18·2 months, and ILD onset occurred at a median of 8·1 months. With 29% of patients still on treatment at data cutoff, late-onset ILD risk beyond 2 years remains incompletely characterized.

• Open-label design and PFS assessment: Although PFS was assessed by BICR (mitigating bias), the open-label design could influence treatment decisions, timing of imaging, and patient-reported symptom assessment. Investigator-assessed PFS (HR 0·30) was consistent with BICR PFS (HR 0·33), providing reassurance.

Clinical Implications

Where This Fits in the Treatment Sequence

DESTINY-Breast03 established trastuzumab deruxtecan as the preferred second-line therapy for HER2-positive metastatic breast cancer, displacing trastuzumab emtansine. In the current (2026) treatment algorithm per NCCN guidelines [3]: - First-line: Taxane + trastuzumab + pertuzumab - Second-line: Trastuzumab deruxtecan (DESTINY-Breast03) - Third-line and beyond: T-DM1, tucatinib + trastuzumab + capecitabine, or other HER2-directed options

Practical Considerations

• Dosing: T-DXd 5·4 mg/kg IV every 3 weeks. Treatment continues until progression or unacceptable toxicity.
• ILD monitoring: Baseline CT of the chest. Advise patients to report new or worsening cough, dyspnea, or fever immediately. Per FDA prescribing information [2], permanently discontinue for grade ≥2 ILD.
• Antiemetic prophylaxis: Nausea occurred in 77% of T-DXd patients (grade ≥3: 7%). Proactive antiemetic regimen is essential; T-DXd is classified as moderately emetogenic.
• Hematologic monitoring: Neutropenia (grade ≥3: 16%) and anemia (grade ≥3: 9%) are common. Regular CBC monitoring is required.
• Dose modifications: Dose reductions occurred in 25% and dose interruptions in 42% of patients. Clinicians should be familiar with the dose modification guidelines in the prescribing information [2].
• Median treatment duration was 18·2 months — substantially longer than the 6·9 months for T-DM1, reflecting both longer disease control and the commitment to ongoing treatment logistics.

Unanswered Questions

The two most practice-relevant questions remain: (1) what is the optimal therapy after progression on T-DXd in the second-line setting — T-DM1, tucatinib-based therapy, or an alternative approach — and (2) whether the 17% of T-DM1 patients who received subsequent T-DXd substantially attenuated the OS difference, and what the true survival benefit would be without this crossover effect.

Post-Progression Options

Of patients who discontinued study treatment, 130 (71%) of 182 in the T-DXd arm and 191 (79%) of 243 in the T-DM1 arm received subsequent anticancer systemic therapies. Notably, 64 (35%) of T-DXd patients who discontinued received T-DM1 subsequently, and 42 (17%) of T-DM1 patients received T-DXd as subsequent therapy.

Regulatory and Guideline Status

Regulatory

• FDA: Trastuzumab deruxtecan (Enhertu) received regular approval from the FDA in May 2022 for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy, based on the DESTINY-Breast03 results. This approval effectively replaced the prior accelerated approval limited to third-line and later use.
• EMA: Marketing authorization for second-line HER2-positive metastatic breast cancer.

⚠️ Regulatory status verified as of March 2026. Confirm current approval status and labeled indications before clinical use at FDA.gov.

Guidelines

• NCCN: Trastuzumab deruxtecan is listed as a preferred regimen for HER2-positive metastatic breast cancer in the second-line setting (Category 1) based on DESTINY-Breast03, in the NCCN Clinical Practice Guidelines in Oncology: Breast Cancer [3].

Companion Diagnostics

HER2-positive status must be confirmed by an FDA-approved test (IHC 3+ or ISH-positive). Central confirmation was required for trial enrollment.

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com, a clinical intelligence platform delivering structured, source-traced oncology trial analysis to practicing clinicians. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces directly to its source publication. Zero calculation. Zero editorializing. Zero hallucination.

Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

Disclaimer

This article is intended for healthcare professionals only. It is not medical advice and should not be used as a substitute for professional clinical judgment. Treatment decisions should be made in consultation with qualified healthcare providers based on individual patient circumstances.

All trial data presented in this article are sourced directly from the published clinical trial report and its supplementary materials. Numbers are reproduced exactly as reported; no calculations, derivations, or estimates have been performed.

Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability.

Comparator trial data presented in Section 8 are sourced from their respective published reports and are provided for contextual purposes only. Cross-trial comparisons have inherent limitations and should not be interpreted as direct statistical comparisons.

References

1. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401(10371):105-117. doi:10.1016/S0140-6736(22)02420-5
2. Enhertu (fam-trastuzumab deruxtecan-nxki) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
4. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-1791.
5. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597-609.